News | Heart Failure | February 22, 2017

New RightSTEPS Educational Initiative to Drive Change in Clinician Prescribing Behavior for Chronic Heart Failure

Blended-learning initiative provides comprehensive education to empower clinicians to take the RightSTEPS to treat the right patients with the right drugs at the right dose at the right time

ACC, Haymarket Medical Education, HME, myCME, RightSTEPS initiative, prescribing behavior, chronic heart failure

February 22, 2017 — The American College of Cardiology (ACC), Haymarket Medical Education (HME) and myCME have joined forces to develop RightSTEPS: Optimizing Medical Therapy for Chronic Heart Failure. This long-term education initiative aims to help clinicians follow prescribing guidelines to reduce hospitalizations and readmissions and to improve patient outcomes to address the 75 percent of chronic heart failure (HF) patients who do not receive optimal doses of guideline-recommended drugs.

Launching in 2017, with additional education to be added regularly throughout the year, the program is overseen by leading experts in HF treatment, including Akshay S. Desai, M.D., MPH, FACC, director, heart failure disease management, Cardiovascular Division, Brigham and Women’s Hospital and associate professor of ,edicine, Harvard Medical School. The curriculum includes American College of Cardiology/American Heart Association guideline-driven medical therapy, and it enables clinicians to:

  • Learn via a dedicated online Cardiology Learning Center on myCME offering self-paced, personalized educational activities that are eligible for up to 16 continuing medical education (CME)/continuing nursing education (CNE) complimentary credits, including individualized treatments for various gender and racial/ethnic populations;
  • Practice during face-to-face live meetings at regional healthcare systems, with parallel sessions for patients and caregivers at Veterans Affairs hospitals; and
  • Perform and receive customized online coaching that qualifies as a Centers for Medicare & Medicaid Services (CMS) Quality Payment Program Improvement Activity under the new Merit-based Incentive Payment System (MIPS).

“Improving heart health is at the core of the ACC’s mission,” said Desai, ACC RightSTEPS chair and course director. “With RightSTEPS, medical professionals treating heart failure patients have easier access to the tools they need to make informed, guideline-driven decisions and provide their patients with the highest quality care.”

“Successful treatment of chronic HF depends on both medical knowledge and ongoing dialogue,” said Priya Wanchoo, M.D., medical director of myCME. “We’re pleased the education we develop with the ACC for RightSTEPS will have a dedicated home on myCME. We believe it will provide clinicians a support center for their efforts in providing optimal patient care.”

Supported by an independent educational grant from Novartis Pharmaceuticals Corporation, the curriculum is designed for the range of clinicians who provide care for patients with chronic HF, including cardiologists, internists, primary care physicians, nurses, nurse practitioners and physician assistants. To further close the circle and improve performance, it includes education geared for patients with chronic HF and their caregivers.

For more information: www.mycme.com/rightsteps


Related Content

News | Heart Failure

April 16, 2024 — Each year more than 500,000 Americans undergo percutaneous coronary intervention, or PCI, a minimally ...

Home April 16, 2024
Home
News | Heart Failure

April 12, 2024 — University of Virginia School of Medicine researchers have discovered a gene on the Y chromosome that ...

Home April 12, 2024
Home
News | Heart Failure

April 2, 2024 — People who use e-cigarettes are significantly more likely to develop heart failure compared with those ...

Home April 02, 2024
Home
News | Heart Failure

March 29, 2024 — V-Wave announced it will present late-breaking data from its RELIEVE-HF pivotal trial at the American ...

Home March 29, 2024
Home
News | Heart Failure

March 25, 2024 — A team of engineers led by the University of Massachusetts Amherst and including colleagues from the ...

Home March 25, 2024
Home
News | Heart Failure

March 15, 2024 — BioCardia, Inc. , a biotechnology company focused on advancing late-stage cell therapy interventions ...

Home March 15, 2024
Home
News | Heart Failure

March 15, 2024 — BioCardia, Inc., a biotechnology company focused on advancing late-stage cell therapy interventions for ...

Home March 15, 2024
Home
News | Heart Failure

March 13, 2024 — BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of ...

Home March 13, 2024
Home
News | Heart Failure

March 8, 2024 — The Texas Heart Institute, Georgia Institute of Technology (Georgia Tech), North Carolina State ...

Home March 08, 2024
Home
News | Heart Failure

March 5, 2024 — FIRE1 announced that it has completed patient enrollment in the U.S. Early Feasibility Study (FUTURE-HF2 ...

Home March 05, 2024
Home
Subscribe Now